Autopsy report · NCT04172532
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Cause of deathOther
“Other - DSMB decision”
Life of this trial
- Registered 1 year 2 months before it started.
- Suspended: paused, and may or may not restart.
- 92 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 1, Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure; Biospecimen Collection; Computed Tomography; Hypofractionated Radiation Therapy; Magnetic Resonance Imaging; Peposertib
- Participants
- 92 (planned, not actual)
- Sites
- 44
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.